Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.
Learn more about biosimilars and their benefits for patients and healthcare systems.
Effective July 1, 2021, patients covered by Alberta’s public drug plan who take Lovenox enoxaparin are required to switch to an enoxaparin biosimilar by January 10, 2022. All new patient starts for enoxaparin will be covered for a biosimilar.
B.C.’s biosimilar switching policy has had a profound impact on private drug plans in the province, according to TELUS Health claims data for private drug plans.